|
· Blood Plasma Fractionation as an Example of a Path to Greater Profits for Air, Water and Energy (AWE) Suppliers
· $10 billion for High Performance AWE Product LTCOV will be Justified
Blood Plasma Fractionation as an Example of a Path to Greater Profits for Air, Water and Energy (AWE) Suppliers
Lowering the total cost of ownership for AWE products used in blood fractionation can increase supplier EBITA. The McIlvaine initiative explaining this may be found at http://home.mcilvainecompany.com/index.php/other-services/free-news/news-releases/47-uncategorised/news/1691-nr2677
McIlvaine’s primary role is to generate the millions of AWE forecasts and competitor analyses needed by suppliers. This is only possible with the Industrial Internet of Wisdom (IIoW) which relies on knowledge generated by the media, associations and conference organizers.
Blood Plasma is a significant AWE market with innovation driving higher EBITA.
Revenues are approaching $40 billion per year. The top 10 producers account for more than 50 million liters per year.
Products include immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products.
Processes include fractionation, concentration, pre- and post-virus inactivation, purification and buffer production, storage and distribution.
CRB, a provider of integrated systems for the biotechnology industry, has given a number of AWE insights to pursue including
· Pre-built cleanroom wall systems and prefabricated pipe racks for hygienic piping
· Alternative separation choices
o Centrifuges (disc or other)
o Depth filters (filter press, cartridge, rotating disc)
o Chromatography
Instrumentation revenues are affected by equipment choices but can also drive them. For example CRB believes that better automated filter presses will gain market share from centrifuges.
IIoT & Remote O&M includes guide, control, and measure products. It provides the needed total cost of ownership factors for components and consumables. It therefore should be used for purchasing decisions.
New developments need continuous assessment. GEA has introduced its fully automatic separator, the hycon®, which enables one-touch production for separation of blood plasma and plasma proteins in cleanroom applications.
Filtration media choices are crucial. Depth filters are the first choice for the separation of precipitates and clarification processes in dedicated fractionation steps according to Eaton. Because proteins and process parameters, such as ethanol concentration and pH vary throughout the process, it is essential to choose the right filter media for the appropriate process.
EMD Millipore recommends Single-Pass Tangential Flow Filtration (SPTFF) for concentrating a plasma-derived Immunoglobulin G (IgG) solution from 10% to 20%. Alternative filter choices have different pressure requirements. This affects pump and valve selection.
Pall tangential cross flow filtration is a popular option.
The pursuit of wisdom for blood fractionation AWE will be pursued on a continuing basis. It will include articles to be published.
Articles: February - March 2022
· International Filtration News: True Cost of Filters, Separators and Media for Plasma Fractionation (McIlvaine True Cost articles appear in each issue)
· Valve World Americas: Process and CIP Valves for Plasma Fractionation
· Pump Engineer: Pumps for processing, cooling and CIP in Plasma Fractionation
· Hose & Coupling: H&C for processing, cooling and CIP in Plasma Fractionation
· Stainless Steel World Americas: Stainless Steel for processing, cooling and CIP in Plasma Fractionation
Exhibitions: March
FILTEXPO, March 29-31, Miami. Route map to speakers, exhibitors and attending experts who have wisdom relative to plasma fractionation filters and media
Articles and Exhibitions: April 2022 and subsequently
There are plans for additional articles in cleanroom and pharmaceutical magazines. Mark Allen Group through Filtration and Separation is a sponsor of FILTEXPO. It also owns World Pumps which will be contacted for future articles.
The IIoW approach for bioethanol is explained at http://home.mcilvainecompany.com/index.php/other-services/free-news/news-releases/47-uncategorised/news/1690-nr2676
The niches in the pharmaceutical industry are listed at http://home.mcilvainecompany.com/index.php/other-services/free-news/news-releases/47-uncategorised/news/1688-nr2674
For more information on this program contact Bob McIlvaine at rmcilvaine@mcilvainecompany.com cell 847 226 2391
$10 billion for High Performance AWE Product LTCOV will be Justified
The revenues for high performance Flow and Treat purchases are $300 billion per year. For this segment there are a number of related factors forming a causation loop consisting of
Market share
Total cost of ownership (TCO)
Industrial Internet of Wisdom (IIoW)
Lowest Total Cost of Ownership Validation (LTCOV)
Profit margin and total profits
If the LTCOV can be validated in the important niches, the supplier can raise pries and achieve 30% EBITA. The revenues would rise to $345 billion.
The niche forecasts and validation would be the foundation of the business strategy. This effort will be in place of some of the sales activity. Also a small percentage of the potential increased EBITA will be applied to the LTCOV program. Therefore, expenditures of $10 billion or more are available to execute the LTCOV strategy.
The validation will require extensive use of the media, conferences, exhibitions, and webinars in addition to the market research.
The complete program is outlined at www.mcilvainecompany.com
Bob McIlvaine can answer your questions at 847 226 2391 rmcilvaine@mcilvianecompany.com
|
